Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FHIT | P49789 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19947264 | 1.00 | POLB (0.40) | POLBL3MBTL1SMN1; SMN2FHITTSHR | |
| SCHEMBL25424099 | 0.91 | TSHR (0.41) | POLBL3MBTL1SMN1; SMN2TSHRHRH3 | |
| SCHEMBL25424091 | 0.91 | TSHR (0.41) | POLBL3MBTL1SMN1; SMN2TSHRHRH3 | |
| SCHEMBL29039246 | 0.89 | TSHR (0.40) | POLBL3MBTL1SMN1; SMN2TSHREPHX2 | |
| SCHEMBL4295231 | 0.86 | EPHX2 (0.40) | SMN1; SMN2TSHREPHX2KMT2A | |
| SCHEMBL19947209 | 0.84 | ALDH1A1 (0.40) | POLBL3MBTL1SMN1; SMN2TSHRHRH3 | |
| SCHEMBL2041988 | 0.84 | ALDH1A1 (0.40) | POLBL3MBTL1SMN1; SMN2TSHRHRH3 | |
| SCHEMBL5643023 | 0.83 | POLB (0.42) | POLBL3MBTL1HRH3FFAR1 | |
| SCHEMBL28153696 | 0.83 | POLB (0.42) | POLBL3MBTL1HRH3FFAR1 | |
| SCHEMBL28881907 | 0.81 | POLB (0.43) | POLBL3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885SMN1; SMN2 2633/4885 |
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | POLB 3566/4885L3MBTL1 3976/4885SMN1; SMN2 4865/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885SMN1; SMN2 2633/4885 |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | POLB 3566/4885L3MBTL1 3976/4885SMN1; SMN2 4865/4885 |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | POLB 578/4885L3MBTL1 4285/4885SMN1; SMN2 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.